市場調査レポート

商品コード

1435104

α1アンチトリプシン欠乏症治療薬市場：治療法、投与経路、流通チャネル別- 世界予測2024-2030年

Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment (Augmentation Therapy, Bronchodilators, Corticosteroids), Route of Administration (Inhalation, Injection, Oral), Distribution Channel - Global Forecast 2024-2030

出版日: 2024年01月15日 | 発行: 360iResearch

| ページ情報: 英文 198 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 746,257円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 903,397円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,060,537円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,374,817円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

α1アンチトリプシン欠乏症治療薬市場規模は2023年に30億2,000万米ドルと推計され、2024年には32億6,000万米ドルに達し、CAGR 9.15%で2030年には55億7,000万米ドルに達すると予測されます。

α1アンチトリプシン欠乏症治療薬の世界市場

主な市場の統計
基準年[2023］	30億2,000万米ドル
予測年[2024］	32億6,000万米ドル
予測年 [2030]	55億7,000万米ドル
CAGR（%）	9.15%

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはα1アンチトリプシン欠乏症治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、α1アンチトリプシン欠乏症治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-α1アンチトリプシン欠乏症治療薬市場の市場規模および予測は？

2-α1アンチトリプシン欠乏症治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-α1アンチトリプシン欠乏症治療薬市場における技術動向と規制の枠組みは？

4-α1アンチトリプシン欠乏症治療薬市場における主要ベンダーの市場シェアは？

5-α1アンチトリプシン欠乏症治療薬市場への参入に適した形態や戦略的手段は？

市場力学
- 促進要因
  - 人口におけるα1アンチトリプシン欠乏症の発生率の上昇
  - 早期診断と予防ケアに対する意識の高まり
- 抑制要因
  - 研究開発に伴う高額なコストと熟練した専門家の不足
- 機会
  - 新しいアルファ1アンチトリプシン欠乏症治療法に関する最新の調査
  - ヘルスケアインフラを最新化するための投資の増加
- 課題
  - α1アンチトリプシン欠損症の診断に伴う制限
市場セグメンテーション分析
市場動向分析
高インフレの累積的影響
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
規制の枠組み

第6章 α1アンチトリプシン欠乏症治療薬市場治療別

増強療法
気管支拡張薬
コルチコステロイド
酸素療法

第7章 α1アンチトリプシン欠乏症治療薬市場：投与経路別

吸入
注射
オーラル

第8章 α1アンチトリプシン欠乏症治療薬市場：流通チャネル別

オフライン
- 病院薬局
- 小売薬局
オンライン

第9章南北アメリカのα1アンチトリプシン欠乏症治療薬市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第10章アジア太平洋地域のα1アンチトリプシン欠乏症治療薬市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第11章欧州・中東・アフリカのα1アンチトリプシン欠乏症治療薬市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第12章競合情勢

FPNVポジショニングマトリクス
市場シェア分析：主要企業別
競合シナリオ主要企業別の分析

第13章競争力のあるポートフォリオ

主要な企業プロファイル
- Abeona Therapeutics Inc
- Alnylam Pharmaceuticals, Inc.
- Apic Bio
- Arrowhead Pharmaceuticals, Inc.
- AstraZeneca PLC
- Baxter International Inc.
- Cedars-Sinai Health System
- Centessa Pharmaceuticals PLC
- Chiesi Farmaceutici S.p.A.
- CSL Limited
- Curaxys S.L.
- Dicerna Pharmaceuticals, Inc
- GlaxoSmithKline PLC
- Grifols, S.A.
- Inhibrx, Inc.
- Intellia Therapeutics, Inc.
- Kamada Ltd.
- Krystal Biotech, Inc.
- LFB Biomedicaments S.A.
- Mereo Biopharma Group PLC
- Novo Nordisk A/S
- Pfizer, Inc.
- PH PHARMA CO. LTD
- Takeda Pharmaceutical Company Limited
- Vertex Pharmaceuticals Incorporated
主要な製品ポートフォリオ

第14章付録

ディスカッションガイド
ライセンスと価格について

図表

LIST OF FIGURES

FIGURE 1. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET DYNAMICS
FIGURE 7. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 8. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

TABLE 1. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 6. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 15. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 17. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 33. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 37. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 55. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 59. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 60. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 63. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 67. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 68. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 75. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 79. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 83. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 87. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 91. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 95. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 96. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 104. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 105. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 108. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 109. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 112. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 116. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 120. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 121. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 128. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 129. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 140. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 144. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 145. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 148. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 164. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 165. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 172. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 176. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 177. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 188. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 189. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 190. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET LICENSE & PRICING

Product Code: MRR-C002B1C99874

[198 Pages Report] The Alpha 1 Antitrypsin Deficiency Treatment Market size was estimated at USD 3.02 billion in 2023 and expected to reach USD 3.26 billion in 2024, at a CAGR 9.15% to reach USD 5.57 billion by 2030.

Global Alpha 1 Antitrypsin Deficiency Treatment Market

KEY MARKET STATISTICS
Base Year [2023]	USD 3.02 billion
Estimated Year [2024]	USD 3.26 billion
Forecast Year [2030]	USD 5.57 billion
CAGR (%)	9.15%

Alpha 1 Antitrypsin Deficiency Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alpha 1 Antitrypsin Deficiency Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alpha 1 Antitrypsin Deficiency Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alpha 1 Antitrypsin Deficiency Treatment Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc, Alnylam Pharmaceuticals, Inc., Apic Bio, Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Cedars-Sinai Health System, Centessa Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., CSL Limited, Curaxys S.L., Dicerna Pharmaceuticals, Inc, GlaxoSmithKline PLC, Grifols, S.A., Inhibrx, Inc., Intellia Therapeutics, Inc., Kamada Ltd., Krystal Biotech, Inc., LFB Biomedicaments S.A., Mereo Biopharma Group PLC, Novo Nordisk A/S, Pfizer, Inc., PH PHARMA CO. LTD, Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Alpha 1 Antitrypsin Deficiency Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Treatment
- Augmentation Therapy
- Bronchodilators
- Corticosteroids
- Oxygen Therapy
Route of Administration
- Inhalation
- Injection
- Oral
Distribution Channel
- Offline
  - Hospital Pharmacy
  - Retail Pharmacy
- Online
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Alpha 1 Antitrypsin Deficiency Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alpha 1 Antitrypsin Deficiency Treatment Market?

3. What are the technology trends and regulatory frameworks in the Alpha 1 Antitrypsin Deficiency Treatment Market?

4. What is the market share of the leading vendors in the Alpha 1 Antitrypsin Deficiency Treatment Market?

5. Which modes and strategic moves are suitable for entering the Alpha 1 Antitrypsin Deficiency Treatment Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Alpha 1 Antitrypsin Deficiency Treatment Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidences of alpha 1 antitrypsin deficiency among population
  - 5.1.1.2. Growing awareness about early diagnosis and preventive care
- 5.1.2. Restraints
  - 5.1.2.1. High costs associated with R&D and dearth of skilled professionals
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging research on new alpha 1 antitrypsin deficiency treatments
  - 5.1.3.2. Increasing investments to modernize healthcare infrastructure
- 5.1.4. Challenges
  - 5.1.4.1. Limitations associated with a diagnosis of alpha 1 antitrypsin deficiency
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Alpha 1 Antitrypsin Deficiency Treatment Market, by Treatment

6.1. Introduction
6.2. Augmentation Therapy
6.3. Bronchodilators
6.4. Corticosteroids
6.5. Oxygen Therapy

7. Alpha 1 Antitrypsin Deficiency Treatment Market, by Route of Administration

7.1. Introduction
7.2. Inhalation
7.3. Injection
7.4. Oral

8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel

8.1. Introduction
8.2. Offline
- 8.3.1. Hospital Pharmacy
- 8.3.2. Retail Pharmacy
8.3. Online

9. Americas Alpha 1 Antitrypsin Deficiency Treatment Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Abeona Therapeutics Inc
- 13.1.2. Alnylam Pharmaceuticals, Inc.
- 13.1.3. Apic Bio
- 13.1.4. Arrowhead Pharmaceuticals, Inc.
- 13.1.5. AstraZeneca PLC
- 13.1.6. Baxter International Inc.
- 13.1.7. Cedars-Sinai Health System
- 13.1.8. Centessa Pharmaceuticals PLC
- 13.1.9. Chiesi Farmaceutici S.p.A.
- 13.1.10. CSL Limited
- 13.1.11. Curaxys S.L.
- 13.1.12. Dicerna Pharmaceuticals, Inc
- 13.1.13. GlaxoSmithKline PLC
- 13.1.14. Grifols, S.A.
- 13.1.15. Inhibrx, Inc.
- 13.1.16. Intellia Therapeutics, Inc.
- 13.1.17. Kamada Ltd.
- 13.1.18. Krystal Biotech, Inc.
- 13.1.19. LFB Biomedicaments S.A.
- 13.1.20. Mereo Biopharma Group PLC
- 13.1.21. Novo Nordisk A/S
- 13.1.22. Pfizer, Inc.
- 13.1.23. PH PHARMA CO. LTD
- 13.1.24. Takeda Pharmaceutical Company Limited
- 13.1.25. Vertex Pharmaceuticals Incorporated
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

α1アンチトリプシン欠乏症治療薬市場：治療法、投与経路、流通チャネル別- 世界予測2024-2030年

Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment (Augmentation Therapy, Bronchodilators, Corticosteroids), Route of Administration (Inhalation, Injection, Oral), Distribution Channel - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第6章 α1アンチトリプシン欠乏症治療薬市場治療別

第7章 α1アンチトリプシン欠乏症治療薬市場：投与経路別

第8章 α1アンチトリプシン欠乏症治療薬市場：流通チャネル別

第9章南北アメリカのα1アンチトリプシン欠乏症治療薬市場

第10章アジア太平洋地域のα1アンチトリプシン欠乏症治療薬市場

第11章欧州・中東・アフリカのα1アンチトリプシン欠乏症治療薬市場

第12章競合情勢

第13章競争力のあるポートフォリオ

第14章付録

LIST OF FIGURES

LIST OF TABLES

This research report categorizes the Alpha 1 Antitrypsin Deficiency Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Alpha 1 Antitrypsin Deficiency Treatment Market, by Treatment

7. Alpha 1 Antitrypsin Deficiency Treatment Market, by Route of Administration

8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel

9. Americas Alpha 1 Antitrypsin Deficiency Treatment Market

10. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market

11. Europe, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market

12. Competitive Landscape

13. Competitive Portfolio

14. Appendix

α1アンチトリプシン欠乏症治療薬市場：治療法、投与経路、流通チャネル別- 世界予測2024-2030年

Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment (Augmentation Therapy, Bronchodilators, Corticosteroids), Route of Administration (Inhalation, Injection, Oral), Distribution Channel - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 α1アンチトリプシン欠乏症治療薬市場治療別

第7章 α1アンチトリプシン欠乏症治療薬市場：投与経路別

第8章 α1アンチトリプシン欠乏症治療薬市場：流通チャネル別

第9章 南北アメリカのα1アンチトリプシン欠乏症治療薬市場

第10章 アジア太平洋地域のα1アンチトリプシン欠乏症治療薬市場

第11章 欧州・中東・アフリカのα1アンチトリプシン欠乏症治療薬市場

第12章 競合情勢

第13章 競争力のあるポートフォリオ

第14章 付録

LIST OF FIGURES

LIST OF TABLES

This research report categorizes the Alpha 1 Antitrypsin Deficiency Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Alpha 1 Antitrypsin Deficiency Treatment Market, by Treatment

7. Alpha 1 Antitrypsin Deficiency Treatment Market, by Route of Administration

8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel

9. Americas Alpha 1 Antitrypsin Deficiency Treatment Market

10. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market

11. Europe, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market

12. Competitive Landscape

13. Competitive Portfolio

14. Appendix

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第9章南北アメリカのα1アンチトリプシン欠乏症治療薬市場

第10章アジア太平洋地域のα1アンチトリプシン欠乏症治療薬市場

第11章欧州・中東・アフリカのα1アンチトリプシン欠乏症治療薬市場

第12章競合情勢

第13章競争力のあるポートフォリオ

第14章付録